| 1. |
- Ade, P. A. R., et al.
(author)
-
Planck 2015 results XXVI. The Second Planck Catalogue of Compact Sources
- 2016
-
In: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 594
-
Journal article (peer-reviewed)abstract
- The Second Planck Catalogue of Compact Sources is a list of discrete objects detected in single-frequency maps from the full duration of the Planck mission and supersedes previous versions. It consists of compact sources, both Galactic and extragalactic, detected over the entire sky. Compact sources detected in the lower frequency channels are assigned to the PCCS2, while at higher frequencies they are assigned to one of two subcatalogues, the PCCS2 or PCCS2E, depending on their location on the sky. The first of these (PCCS2) covers most of the sky and allows the user to produce subsamples at higher reliabilities than the target 80% integral reliability of the catalogue. The second ( PCCS2E) contains sources detected in sky regions where the diffuse emission makes it difficult to quantify the reliability of the detections. Both the PCCS2 and PCCS2E include polarization measurements, in the form of polarized flux densities, or upper limits, and orientation angles for all seven polarization-sensitive Planck channels. The improved data-processing of the full-mission maps and their reduced noise levels allow us to increase the number of objects in the catalogue, improving its completeness for the target 80% reliability as compared with the previous versions, the PCCS and the Early Release Compact Source Catalogue (ERCSC).
|
|
| 2. |
|
|
| 3. |
- Rosati, P., et al.
(author)
-
Multi-wavelength study of XMMU J2235.3-2557 : the most massive galaxy cluster at z > 1
- 2009
-
In: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 508:2, s. 583-591
-
Journal article (peer-reviewed)abstract
- Context. The galaxy cluster XMMU J2235.3-2557 (hereafter XMM2235), spectroscopically confirmed at z = 1.39, is one of the most distant X-ray selected galaxy clusters. It has been at the center of a multi-wavelength observing campaign with ground and space facilities. Aims. We characterize the galaxy populations of passive members, the thermodynamical properties and metal abundance of the hot gas, and the total mass of the system using imaging data with HST/ACS (i(775) and z(850) bands) and VLT/ISAAC (J and K-S bands), extensive spectroscopic data obtained with VLT/FORS2, and deep (196 ks) Chandra observations. Methods. Chandra data allow temperature and metallicity to be measured with good accuracy and the X-ray surface brightness profile to be traced out to 1' (or 500 kpc), thus allowing the mass to be reliably estimated. Out of a total sample of 34 spectroscopically confirmed cluster members, we selected 16 passive galaxies (without detectable [OII]) within the central 2' (or 1 Mpc) with ACS coverage, and inferred star formation histories for subsamples of galaxies inside and outside the core by modeling their spectrophotometric data with spectral synthesis models. Results. Chandra data show a regular elongated morphology, closely resembling the distribution of core galaxies, with a significant cool core. We measure a global X-ray temperature of kT = 8.6(-1.2)(+1.3) keV (68% confidence), which we find to be robust against several systematics involved in the X-ray spectral analysis. By detecting the rest frame 6.7 keV Iron K line in the Chandra spectrum, we measure a metallicity Z = 0.26(-0.16)(+0.20) Z(circle dot). In the likely hypothesis of hydrostatic equilibrium, we obtain a total mass of M-tot( 1Mpc) = (5.9 +/- 1.3) x 10(14) M-circle dot. By modeling both the composite spectral energy distributions and spectra of the passive galaxies in and outside the core, we find a strong mean age radial gradient. Core galaxies, with stellar masses in excess of 10(11) M-circle dot, appear to have formed at an earlier epoch with a relatively short star formation phase (z = 5-6), whereas passive galaxies outside the core show spectral signatures suggesting a prolonged star formation phase to redshifts as low as z approximate to 2. Conclusions. Overall, our analysis implies that XMM2235 is the hottest and most massive bona-fide cluster discovered to date at z > 1, with a baryonic content, both its galaxy population and intracluster gas, in a significantly advanced evolutionary stage at 1/3 of the current age of the Universe.
|
|
| 4. |
- Ajmera, Veeral H., et al.
(author)
-
MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial)
- 2019
-
In: Hepatology. - : WILEY. - 0270-9139 .- 1527-3350. ; 70:5, s. 1531-1545
-
Journal article (peer-reviewed)abstract
- Aramchol, an oral stearoyl-coenzyme-A-desaturase-1 inhibitor, has been shown to reduce hepatic fat content in patients with primary nonalcoholic fatty liver disease (NAFLD); however, its effect in patients with human immunodeficiency virus (HIV)-associated NAFLD is unknown. The aramchol for HIV-associated NAFLD and lipodystrophy (ARRIVE) trial was a double-blind, randomized, investigator-initiated, placebo-controlled trial to test the efficacy of 12 weeks of treatment with aramchol versus placebo in HIV-associated NAFLD. Fifty patients with HIV-associated NAFLD, defined by magnetic resonance imaging (MRI)-proton density fat fraction (PDFF) amp;gt;= 5%, were randomized to receive either aramchol 600 mg daily (n = 25) or placebo (n = 25) for 12 weeks. The primary endpoint was a change in hepatic fat as measured by MRI-PDFF in colocalized regions of interest. Secondary endpoints included changes in liver stiffness using magnetic resonance elastography (MRE) and vibration-controlled transient elastography (VCTE), and exploratory endpoints included changes in total-body fat and muscle depots on dual-energy X-ray absorptiometry (DXA), whole-body MRI, and cardiac MRI. The mean (+/- standard deviation) of age and body mass index were 48.2 +/- 10.3 years and 30.7 +/- 4.6 kg/m(2), respectively. There was no difference in the reduction in mean MRI-PDFF between the aramchol group at -1.3% (baseline MRI-PDFF 15.6% versus end-of-treatment MRI-PDFF 14.4%, P = 0.24) and the placebo group at -1.4% (baseline MRI-PDFF 13.3% versus end-of-treatment MRI-PDFF 11.9%, P = 0.26). There was no difference in the relative decline in mean MRI-PDFF between the aramchol and placebo groups (6.8% versus 1.1%, P = 0.68). There were no differences in MRE-derived and VCTE-derived liver stiffness and whole-body (fat and muscle) composition analysis by MRI or DXA. Compared to baseline, end-of-treatment aminotransferases were lower in the aramchol group but not in the placebo arm. There were no significant adverse events. Conclusion: Aramchol, over a 12-week period, did not reduce hepatic fat or change body fat and muscle composition by using MRI-based assessment in patients with HIV-associated NAFLD (clinicaltrials.gov ID:NCT02684591).
|
|
| 5. |
|
|
| 6. |
- Kappos, Ludwig, et al.
(author)
-
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- 2018
-
In: The Lancet. - 0140-6736 .- 1474-547X. ; 391, s. 1263-1273
-
Journal article (peer-reviewed)abstract
- © 2018 Elsevier Ltd Background: No treatment has consistently shown efficacy in slowing disability progression in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of siponimod, a selective sphingosine 1-phosphate (S1P) receptor 1,5 modulator, on disability progression in patients with SPMS. Methods: This event-driven and exposure-driven, double-blind, phase 3 trial was done at 292 hospital clinics and specialised multiple sclerosis centres in 31 countries. Using interactive response technology to assign numbers linked to treatme nt arms, patients (age 18–60 years) with SPMS and an Expanded Disability Status Scale score of 3·0–6·5 were randomly assigned (2:1) to once daily oral siponimod 2 mg or placebo for up to 3 years or until the occurrence of a prespecified number of confirmed disability progression (CDP) events. The primary endpoint was time to 3-month CDP. Efficacy was assessed for the full analysis set (ie, all randomly assigned and treated patients); safety was assessed for the safety set. This trial is registered with ClinicalTrials.gov, number NCT01665144. Findings: 1651 patients were randomly assigned between Feb 5, 2013, and June 2, 2015 (1105 to the siponimod group, and 546 to the placebo group). One patient did not sign the consent form, and five patients did not receive study drug, all of whom were in the siponimod group. 1645 patients were included in the analyses (1099 in the siponimod group and 546 in the placebo). At baseline, the mean time since first multiple sclerosis symptoms was 16·8 years (SD 8·3), and the mean time since conversion to SPMS was 3·8 years (SD 3·5); 1055 (64%) patients had not relapsed in the previous 2 years, and 918 (56%) of 1651 needed walking assistance. 903 (82%) patients receiving siponimod and 424 (78%) patients receiving placebo completed the study. 288 (26%) of 1096 patients receiving siponimod and 173 (32%) of 545 patients receiving placebo had 3-month CDP (hazard ratio 0·79, 95% CI 0·65–0·95; relative risk reduction 21%; p=0·013). Adverse events occurred in 975 (89%) of 1099 patients receiving siponimod versus 445 (82%) of 546 patients receiving placebo; serious adverse events were reported for 197 (18%) patients in the siponimod group versus 83 (15%) patients in the placebo group. Lymphopenia, increased liver transaminase concentration, bradycardia and bradyarrhythmia at treatment initiation, macular oedema, hypertension, varicella zoster reactivation, and convulsions occurred more frequently with siponimod than with placebo. Initial dose titration mitigated cardiac first-dose effects. Frequencies of infections, malignancies, and fatalities did not differ between groups. Interpretation: Siponimod reduced the risk of disability progression with a safety profile similar to that of other S1P modulators and is likely to be a useful treatment for SPMS. Funding: Novartis Pharma AG.
|
|
